Type 1 Diabetes Clinical Trial
— TRIM1Official title:
Intervention for Children With Type 1 Diabetes Targeting Gut Microbes
The goal of this clinical study is to evaluate the effect of nutritional intervention program based on dietary products in the clinical treatment of newly diagnosed children with type 1 diabetes. The main question aims to answer is: whether high fiber diet can protect beta-cell function in children with newly onset type 1 diabetes. Participants will take 12 weeks of high fiber diet intervention and beta-cell function and gut microbiota structure will be analyzed.
Status | Recruiting |
Enrollment | 110 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 12 Years |
Eligibility | Inclusion Criteria: - Diagnosed as type 1 diabetes for the first time according to the diagnostic criteria of the American diabetes Association (ADA) in the past 6 months; - One or more antibodies against GAD65, IAA, IA-2, ICA, and ZNT8 are positive; - The daily total dose of insulin per unit weight was less than 0.5 IU/kg/day three days prior to screening; - Fasting C-peptide (FCP)>0.1 nmol/L (0.3ng/mL); - Age range from 6 to 12 years old; - Have not participated in any other research projects at present; - The guardian signs the informed consent form, the child agrees to the study, and the child over 8 years old signs the informed consent form. Exclusion Criteria: - Suffering from serious chronic and systemic diseases: tumors, immunodeficiency, heart failure, Cushing's syndrome, kidney diseases (including nephrotic syndrome, nephritis, glomerulonephritis, kidney stones, etc.), liver diseases (including autoimmune hepatitis, metabolic liver disease, non-alcoholic fatty liver disease, primary sclerosing cholangitis, chronic, persistent hepatitis, etc.), gallbladder diseases (including cholecystitis, gallstones, etc.), etc; - Suffering from acute or chronic gastrointestinal diseases such as Crohn's disease, ulcerative colitis, gastroesophageal reflux disease, gastrointestinal ulcers, celiac disease, or having defecation three or more times a day in the past week or more, accompanied by watery stools; - Blood pressure = 95th percentile of the same gender, age, and height reference; - Plasma triglycerides of 9 years and below should be = 1.12mmol/L, and triglycerides of 10 years and above should be = 1.46mmol/L; - Used antibiotics within the past month for 3 days or more; - Currently suffering from infectious diseases; - Have the history of gastrointestinal surgery, surgery to remove appendicitis and hernia; - Evidence of pituitary dysfunction; - Use drugs other than insulin that can affect blood sugar levels; - Chromosomal abnormalities (such as trisomy 21 syndrome, Turner syndrome, etc.); - Have taken probiotics and probiotic products continuously for more than 3 days within the first month before enrollment; - Unable to guarantee sufficient time to participate in this project. |
Country | Name | City | State |
---|---|---|---|
China | Children's Hospital of Fudan University | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital of Fudan University | Adfontes (Shanghai) Bio-technology Co.,Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The 2h C-peptide level of the MMTT test | The 2-hour postprandial C-peptide is detected by the mix meal test. The C peptide level is measured using a sensitive, luminescence immunoassay, accurate to 0.01 ng/ml. | 0 week and 12 weeks | |
Secondary | Glycosylated hemoglobin level | The levels of glycosylated hemoglobin is detection by high performance liquid chromatography. Accurate to 0.1%. | 0 week, 4 weeks, 12 weeks and 24 weeks | |
Secondary | Glycated albumin level | The levels of glycated albumin is measured by IMMULITE, accurate to 0.1%. | 0 week, 4 weeks, 12 weeks and 24 weeks | |
Secondary | Fasting C peptide | The level of fasting C peptide is measured using a sensitive, luminescence immunoassay, accurate to 0.01 ng/ml. | 0 week, 4 weeks, 12 weeks and 24 weeks | |
Secondary | Daily insulin dosage | The daily insulin dosage used per kilogram of body weight. IU/kg/d | 0 week, 4 weeks, 12 weeks and 24 weeks | |
Secondary | Area under curve of blood glucose in MMTT test | The level of blood glucose will be tested at 0 min, 30 min, 60 min and 120 min of the mix meal test, and the area under curve will be calculated. | 0 week and 12 weeks | |
Secondary | Area under curve of C peptide in MMTT test | The level of C peptide will be tested at 0 min, 30 min, 60 min and 120 min of the mix meal test, and the area under curve will be calculated. | 0 week and 12 weeks | |
Secondary | Adverse event occurrence rate | The incidence of all recorded adverse events | 0 week, 4 weeks, 12 weeks and 24 weeks | |
Secondary | Body mass index | Body mass index were calculated as weight/(height)^2. | 0 week, 4 weeks, 12 weeks and 24 weeks | |
Secondary | Height | Height accurate to 0.1cm | 0 week, 4 weeks, 12 weeks and 24 weeks | |
Secondary | Weight | Weight accurate to 0.1kg | 0 week, 4 weeks, 12 weeks and 24 weeks | |
Secondary | alanine aminotransferase | The level of alanine aminotransferaseis is measured by enzymatic method. Accurate to 0.01 u/l. | 0 week, 4 weeks, 12 weeks and 24 weeks | |
Secondary | aspartate aminotransferase | The level of aspartate aminotransferase is measured by enzymatic method. Accurate to 0.01 u/l. | 0 week, 4 weeks, 12 weeks and 24 weeks | |
Secondary | Total cholesterol | The level of total cholesterol is measured by enzymatic method. Accurate to 0.01 mmol/L. | 0 week, 4 weeks, 12 weeks and 24 weeks | |
Secondary | Triglyceride | The level of triglyceride is measured by enzymatic method. Accurate to 0.01 mmol/L. | 0 week, 4 weeks, 12 weeks and 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A | |
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 |